Category Archives: News

SOM Biotech at BIO Europe 2018

Europe’s largest annual life science partnering conference was held on November 5-7, 2018 in Copenhagen. BIO Europe serves as a forum for companies across the biotech value chain to meet and do business through one-to-one meetings, workshops, panels and exhibitions. The three-day conference drew over 4,000 industry attendees of high level networking, representing more than 2,000 companies from …

SOM Biotech joins Euronext TechShare Programme

Euronext, the first and largest pan-European stock exchange in the Eurozone, launched its fourth session of TechShare, the only European programme for non-listed companies dedicated to IPOs. The programme is an educational network designed to help fast-growing European tech companies understand the role of capital markets and how these high-potential businesses can help them reach the next stage …

Workshop on Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy

The 3rd Workshop on the Transfer of Scientific Knowledge in Duchenne Muscular Dystrophy was held on September 7, 2018, coinciding with the World Duchenne Awareness Day. The workshop was organized by Duchenne Parent Project España and was focused on the research of the Muscular Dystrophies of Duchenne and Becker in Spain. Participants gathered at the Faculty of Biology of …

World Duchenne Awareness Day 2018

September 7 is World Duchenne Awareness Day. In celebration of this awareness-raising event, SOM Biotech goes casual at the office and joins the “Jeans Day” campaign of Parent Project Muscular Dystrophy. SOM Biotech team Duchenne muscular dystrophy is the most common muscular dystrophy in children. It is a progressive disorder that causes muscles to become …

SOM Biotech at BIT’s 16th Annual Congress of International Drug Discovery Science and Technology 2018

BIT’s 16th Annual Congress of International Drug Discovery Science and Technology (IDDST 2018) was held on 16th-18th August 2018 in Boston, Massachusetts with the theme “Rethinking the Next Big Things in Pharma Innovations”. The congress hosted leading scientists and professionals from the academia and industry worldwide, to discuss the latest developments in drug discovery and therapy. SOM Biotech CEO …

First patient recruited to SOMCT02 Huntington’s disease trial

The SOMCT02 trial has recruited its first patient on 8th August 2018 at the Hospital Clínic de Barcelona, under the leadership of Dr. Esteban Muñoz. This indicates that the trial is now fully underway. SOMCT02 is a Phase 2a proof-of-concept and is designed as a randomized, double-blind, placebo-controlled, 2-arm, 27-week study to evaluate the safety and efficacy of …

SOM Biotech presents to the BIO.NRW Investors Circle

This year, SOM Biotech was invited to present to the Investors Circle of the Business Angel Network of BIO.NRW on the 9th of July in Dusseldorf, Germany. SOM Biotech CEO Dr. Raúl Insa presented the company, highlighting its proven business model to the attending investors. The presentation platform is held three to four times a year in a strictly confidential …

SOM Biotech receives approval to start Huntington’s disease trial

SOM Biotech has received on 18th June 2018 the approval of the Clinical Trial Application (CTA), the European IND equivalent, from the Spanish Drug Agency (AEMPS) to conduct its Phase IIa, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of SOM3355 in patients with choreic movements associated with Huntington’s disease. The study will be conducted in four major hospitals in …